Wednesday, July 23, 2014





Merck: FDA reviewing its ragweed allergy therapy


May 08. 2013 1:39PM
Associated Press

Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.


Merck's latest application is for an allergy immunotherapy tablet for ragweed allergies that dissolves under the tongue. Patients in studies of the tablet took it daily for a year.


It could become an alternative to months of uncomfortable allergy shots. Both methods gradually desensitize the immune system to the substance triggering the allergic reaction.


In March, the Whitehouse Station, N.J., company said the FDA was reviewing its application for an immunotherapy tablet for grass pollen allergies.


Merck expects FDA rulings on both still-unnamed treatments in 2014's first half.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds